SIRT1 and chronic myelogenous leukemia, BCR-ABL1 positive: Studies with Hsp90 protein inhibitors and SIRT1 inhibitors have identified that both have a characteristic therapeutic effect, allowing greater sensitivity to recurrent therapies for CML cells that have resistance to multiple drugs [50].